Like patients with rare diseases in their families. As a result of the Orphan Drug act, there have been important advances in research on and treatment for rare diseases. Unfortunately, The Trump administration's actions have risked rolling back progress [in drug development for rare diseases]. The scientists and researchers at the National Institute of Health who would have previously received funding to develop innovative life saving treatments for rare diseases are losing access to grant funding and heading to other countries with more reliable opportunities. (01:35–01:51)
CLAIM
Asserts that the Trump administration's actions threaten progress in drug development for rare diseases.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
